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NeBACKGROUND Anticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although
an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be
an effective alternative to heparin as the procedural anticoagulant agent in this setting.
OBJECTIVES The goal of this study was to determine whether bivalirudin offers an alternative to heparin as the
procedural anticoagulant agent in patients undergoing TAVR.
METHODS A total of 802 patients with aortic stenosis were randomized to undergo transfemoral TAVR with bivalirudin
versus unfractionated heparin during the procedure. The 2 primary endpoints were major bleeding within 48 h or before
hospital discharge (whichever occurred ﬁrst) and 30-day net adverse clinical events, deﬁned as the combination of major
adverse cardiovascular events (all-cause mortality, myocardial infarction, or stroke) and major bleeding.
RESULTS Anticoagulation with bivalirudin versus heparin did not meet superiority because it did not result in signiﬁ-
cantly lower rates of major bleeding at 48 h (6.9% vs. 9.0%; relative risk: 0.77; 95% conﬁdence interval [CI]: 0.48 to
1.23; p ¼ 0.27) or net adverse cardiovascular events at 30 days (14.4% vs. 16.1%; relative risk: 0.89; 95% CI: 0.64 to
1.24; risk difference: –1.72; 95% CI: –6.70 to 3.25; p ¼ 0.50); regarding the latter, the prespeciﬁed noninferiority
hypothesis was met (pnoninferiority < 0.01). Rates of major adverse cardiovascular events at 48 h were not signiﬁcantly
different (3.5% vs. 4.8%; relative risk: 0.73; 95% CI: 0.37 to 1.43; p ¼ 0.35). At 48 h, the bivalirudin group had
signiﬁcantly fewer myocardial infarctions but more acute kidney injury events than the heparin group; at 30 days, these
differences were no longer signiﬁcant.
CONCLUSIONS In this randomized trial of TAVR procedural pharmacotherapy, bivalirudin did not reduce rates of major
bleeding at 48 h or net adverse cardiovascular events within 30 days compared with heparin. Although superiority was
not shown, the noninferiority hypothesis was met with respect to the latter factor. Given the lower cost, heparin should
remain the standard of care, and bivalirudin can be an alternative anticoagulant option in patients unable to receive
heparin in TAVR. (International, Multi-center, Open-label, Randomized Controlled Trial in Patients Undergoing TAVR to
Determine the Treatment Effect [Both Safety and Efﬁcacy] of Using Bivalirudin Instead of UFH [BRAVO-2/3];
NCT01651780) (J Am Coll Cardiol 2015;66:2860–8) © 2015 by the American College of Cardiology Foundation.m *The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York;
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AB BR E V I A T I O N S
AND ACRONYM S
BARC = Bleeding Academic
Research Consortium
CI = conﬁdence interval
TAVR = transcatheter aortic
valve replacement
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2861A ortic stenosis affects 1% to 4% of the generalpopulation, with a higher incidence amongelderly subjects (1). Although surgical aortic
valve replacement has been the mainstay of treat-
ment, transcatheter aortic valve replacement (TAVR)
was introduced for patients deemed inoperable or at
high surgical risk (2). TAVR has rates of major cardio-
vascular events comparable to open surgery and is su-
perior to conservative treatment (3–6), but it still has
signiﬁcant complications. In randomized trials and
daily practice, unfractionated heparin has been the
standard empiric procedural anticoagulation regimen
for TAVR. Although partial or complete reversal of
heparin with protamine can be used, practice pat-
terns vary, with guideline statements based on expert
consensus rather than on evidence from randomized
trials (2). The rapid expansion of TAVR procedures
worldwide necessitates dedicated clinical investiga-
tion in the ﬁeld of periprocedural pharmacology,
with the goal of building a robust evidence base,
deriving appropriate practice guidelines, and further
improving clinical outcomes.SEE PAGE 2869Bivalirudin is a reversible direct thrombin inhibitor
with a half-life of 25 min; it reduces major bleeding
while providing stable effective anticoagulation in
the setting of percutaneous coronary interventions
compared with other regimens (7–12). The goal of the
present prospective study was to examine whether
bivalirudin offers an alternative to heparin as a pro-
cedural anticoagulant agent in patients undergoing
TAVR as tested in retrospective studies (13,14).
METHODS
The BRAVO-3 (Effect of Bivalirudin on Aortic Valve
Intervention Outcomes-3) trial was an open-label,
randomized controlled trial comparing bivalirudin
with unfractionated heparin in high-risk or inoper-
able patients undergoing TAVR, conducted inkkHelios Heart Center Siegburg, Siegburg, Germany; {{Universität Leipzig,
Rouen, France; ***Department of Cardiology and INSERM UMR 1011, Univers
de Cardiologie de Montreal, Montreal, Quebec, Canada; zzzKlinikum links d
University Hospital Basel, Basel, Switzerland; kkkPoliclinico Umberto I, R
Germany; ###Deutsches Herzzentrum München, Technische Universität M
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Herzzentrum München, Technische Universität München, Munich, Germany
Mehran, and Fach have received grants from TheMedicines Company (modest
Medicines Company. Dr. Windecker has received research grants (to the institu
Bernstein, Deliargyris, and Wijngaard and Mrs. Lechthaler are employees of The
that they haveno relationships relevant to the contents of this paper todisclose. D
Manuscript received October 4, 2015; accepted October 5, 2015.31 European and North American sites (15).
Clinical follow-up was performed on days 1
and 2, on the day of hospital discharge, and
30 days post-procedure.
The executive committee governed all as-
pects of the clinical trial. The Icahn School of
Medicine at Mount Sinai clinical coordinating
center was responsible for the study design;
the identiﬁcation, education, and training of partici-
pating sites, in close collaboration with the sponsor;
study management; and organization and conduct of
the study committees (Online Appendix). The study
sponsor was responsible for funding; protocol devel-
opment in collaboration with the executive commit-
tee and the clinical coordinating center; on-site
monitoring and safety surveillance; statistical ana-
lyses; and data management. The institutional review
board at each site approved the study protocol and
activities. An independent clinical events committee
reviewed and adjudicated all major clinical events.
An independent data safety monitoring board was
responsible for study oversight and the ﬁnal sample
size recommendation (adaptive study design).
STUDY POPULATION. Patients with aortic stenosis
who were $18 years of age, at high surgical risk
(deﬁned as a European System for Cardiac Operative
Risk Evaluation score of $18, or deemed inoperable),
and scheduled for TAVR via transfemoral access were
eligible for enrollment. The main exclusion criteria
were planned surgical cutdown access; presence of a
previous mechanical or mitral bioprosthetic valve;
severe left ventricular dysfunction (ejection frac-
tion <15%); minimal luminal diameter <6.5 mm for
the common femoral artery; severe aortic or mitral
regurgitation; concurrent percutaneous coronary
intervention; recent bleeding or neurological event;
and dialysis dependence. The full lists of inclusion
and exclusion criteria are provided in the Online
Appendix. All patients provided written informed
consent.Herzzentrum, Leipzig, Germany; ##CHU de Rouen,
ity Hospital, and CHRU Lille, Lille, France; yyyInstitut
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2862STUDY MEDICATIONS. To achieve therapeutic levels
of anticoagulation, bivalirudin (Angiomax/Angiox,
The Medicines Company, Parsippany, New Jersey)
was administered as an initial bolus of 0.75 mg/kg,
followed by a continuous infusion at a rate of
1.75 mg/kg/h in patients with an estimated glomerular
ﬁltration rate $60 ml/min. The initial bolus was
administered either through the valve delivery
sheath or as an intravenous systemic administration.
The intravenous infusion was initiated immediately
after the bolus dose and stopped after successful
valve implantation. The infusion rate was decreased
to 1.4 mg/kg/h in patients with an estimated
glomerular ﬁltration rate of 30 to 59 ml/min and to
1 mg/kg/h in patients with a glomerular ﬁltration
rate <30 ml/min. Heparin dosing and administration
included a recommended target activated clotting
time of >250 s; the decision for reversal with prot-
amine at the end of the procedure was subject to
standard local institution practice. Patients under-
went TAVR according to the standard practices at
each site, including the use of pre-procedural medi-
cations and the selection of a commercially available
valve system. After the procedure, study recommen-
dations were for patients to receive aspirin at a
dosage of 75 to 100 mg/day for at least 1 year and
clopidogrel at 75 mg/day for a period deﬁned by
institutional standard practices.
STUDY OUTCOMES. The ﬁrst co-primary outcomewas
major bleeding (deﬁned as BARC [Bleeding Academic
Research Consortium] $3b [16]; detailed in the Online
Appendix) within 48 h or before hospital discharge,
whichever occurred ﬁrst. The second co-primary
outcome was the rate of net adverse cardiovascular
events within 30 days, deﬁned as the composite of
major adverse cardiovascular events (all-cause mor-
tality, myocardial infarction, or stroke) and major
bleeding. Other secondary endpoints included
bleeding deﬁned according to additional bleeding
scales (from the VARC [Valve Academic Research
Consortium], TIMI [Thrombolysis In Myocardial
Infarction], GUSTO [Global Utilization of Streptoki-
nase and Tissue Plasminogen Activator for Occluded
Coronary Arteries], ACUITY/HORIZONS [Acute Cathe-
terization and Urgent Intervention Triage Strat-
egy/Harmonizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction], and
other BARC types [Online Appendix]) and the com-
posite of major adverse cardiovascular events, as well
as its individual components. Other outcomes of
interest included acute kidney injury, transient
ischemic attacks, major vascular complications,
acquired thrombocytopenia, and new post-proceduralatrial ﬁbrillation/ﬂutter. All secondary endpoints were
assessed at 48 h or hospital discharge, whichever
occurred ﬁrst, and at 30 days.
STATISTICAL ANALYSIS. The original sample size
assumed an estimated rate of major bleeding of 19%
in the control group and a relative risk reduction of
47% in the experimental group; thus, a sample size of
522 patients (261 per arm) would be needed for an
80% power to detect a signiﬁcant bleeding reduction
at an alpha level <0.05. The study was also powered
to show noninferiority for 30-day net adverse car-
diovascular events with a margin of 8.0% difference
in event rates. BRAVO-3 had an adaptive sample size
design that included a prospectively planned oppor-
tunity for an increase in the sample size based on
analysis of interim bleeding data after two-thirds of
patients completed 30-day follow-up. After reviewing
the summary report produced by the independent
statistician, the data safety monitoring board issued a
recommendation to continue the trial unmodiﬁed
until the predeﬁned maximum of 800 patients were
enrolled, according to the interim statistical analysis
plan (Online Appendix).
Continuous variables are reported as mean  SD or
median (interquartile range) and were tested by using
the Student t test. Categorical variables are reported
as frequencies and percentages and were tested by
using the chi-square test. The primary data analysis
was performed according to the intention-to-treat
principle. Tabulated event rates were tested by us-
ing the chi-square test. The Kaplan-Meier method
was used for the time-to-event analysis based on all
available follow-up data, and the log-rank test was
used for the comparison. Statistical analyses were
performed by using SAS version 9.2 (SAS Institute,
Inc., Cary, North Carolina).
RESULTS
Between October 2012 and May 2015, a total of 802
patients with severe, symptomatic aortic stenosis
were enrolled at 31 sites in 7 countries and random-
ized to receive bivalirudin (n ¼ 404) versus unfrac-
tionated heparin (n ¼ 398) during TAVR. Eighteen
patients did not undergo the assigned treatment (11 in
the bivalirudin group and 7 in the heparin group) for
the reasons detailed in Figure 1. The 30-day follow-up
data were available for 394 (97.5%) patients in the
bivalirudin group and 388 (97.5%) patients in the
heparin group.
The baseline characteristics of the patients were
well matched between groups (Table 1). The popula-
tion was elderly (mean age 82.3  6.5 years) with a
mean European System for Cardiac Operative Risk
FIGURE 1 Randomization, Management, and Follow-Up at 48 h and 30 Days
803 Underwent
randomization
1 Withdrew consent to use all
patient data
802 Intention-to-treat
population
404 Were assigned to
receive bivalirudin
(8 patients did not have
TAVR)
398 Were assigned to
receive heparin
(4 patients did not have
TAVR)
8 Did not receive bivalirudin
6 Did not undergo TAVR
7 Did not receive
unfractionated heparin
   2 Did not undergo TAVR
3 Received unfractionated
heparin
1 Did not undergo TAVR1 Day 30 visit <23 days
1 Lost to follow-up <23 days
1 Withdrew consent but
allowed data use prior to
withdrawal
2 Physician decision
2 Due to study criteria
2 Other reason
5 Day 30 visit <23 days
2 Lost to follow-up <23 days
1 Physician decision
2 Other reason
394 Completed 30-day
Follow-Up (97.5%)
388 Completed 30-day
Follow-Up (97.5%)
TAVR ¼ transcatheter aortic valve replacement.
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2863Evaluation score of 17.0  10.3%. Overall, 29.8%
(239 of 802) had diabetes mellitus, 19.3% (155 of 802)
had chronic obstructive pulmonary disease, and
10.4% (83 of 800) had experienced prior cerebrovas-
cular events. Procedure and treatment data are
shown in Table 2. An initial heparin bolus of 72.6 
26.8 IU/kg (median 69.4 IU/kg; interquartile range
53.0 to 87.5 IU/kg) was used in the control group.
CLINICAL OUTCOMES. The trial outcomes are sum-
marized in Table 3 and shown in the Central Illustration,
Online Tables 1 to 5, and Online Figure 1. After 48 h of
the TAVR procedure, major bleeding (BARC $3b)
occurred in 6.9% of the bivalirudin-treated patients
compared with 9.0% of the heparin-treated patients(relative risk: 0.77; 95% conﬁdence interval [CI]:
0.48 to 1.23; p ¼ 0.27); the superiority hypothesis
was not met. After 30 days, net adverse cardio-
vascular events occurred in 14.4% of the
bivalirudin-treated patients and in 16.1% of
heparin-treated patients (risk difference: –1.72; 95% CI:
–6.70 to 3.25; relative risk: 0.89; 95% CI: 0.64 to 1.24;
p ¼ 0.50); the pre-speciﬁed noninferiority hypothesis
was met (pnoninferiority <0.01). When noninferiority
was tested in the “per-treatment” population, the
results for 30-day net adverse cardiovascular events
were qualitatively similar: 14.8% for bivalirudin
versus 15.9% for heparin (relative risk: 0.93; 95% CI:
0.67 to 1.29; psuperiority ¼ 0.66; risk difference: –1.14;
95% CI: –6.20 to 3.92; pnoninferiority #0.01).
TABLE 1 Baseline Characteristics of the Study Population
Bivalirudin
(n ¼ 404)
Heparin
(n ¼ 398)
Age, yrs 82.3  6.5 82.3  6.5
Women 195 (48.3) 196 (49.2)
Logistic EuroSCORE, %* 17.2  10.7 16.9  9.9
Median (interquartile range) 15.2 (9-22) 15.4 (9-23)
Diabetes mellitus 125 (30.9) 114 (28.6)
Oral treatment 41 (10.1) 42 (10.6)
Insulin treatment 47 (11.6) 40 (10.1)
Chronic kidney disease
Glomerular ﬁltration rate <30 ml/min 18 (4.5) 22 (5.5)
Glomerular ﬁltration rate 30–59 ml/min 205 (50.7) 193 (48.5)
Peripheral artery disease 60 (14.9) 59/397 (14.9)
Prior stroke/transient ischemic attack 45/403 (11.2) 38/397 (9.6)
Stroke 31/403 (7.7) 26/397 (6.5)
Transient ischemic attack 14/403 (3.5) 12/397 (3.0)
Chronic obstructive pulmonary disease 68 (16.8) 87 (21.9)
Heart disease
Coronary artery disease 209 (51.7) 196/397 (49.4)
Prior myocardial infarction 63/400 (15.8) 53/394 (13.5)
Prior atrial ﬁbrillation 158/403 (39.2) 139/397 (35.0)
Prior ventricular tachycardia 11/391 (2.8) 9/381 (2.4)
Previous coronary bypass graft surgery 61 (15.1) 56 (14.1)
Previous balloon aortic valvuloplasty 29 (7.2) 31/397 (7.8)
Left ventricular ejection fraction, % 53.9  12.8 53.4  12.9
Hemoglobin, g/dl 12.5  1.7 12.7  1.6
Platelet count,  109/l 217.7  73.9 217.2  71.4
Antiplatelet medications as prior maintenance therapy
Aspirin 276/402 (68.7) 272/397 (68.5)
#160 mg 266/402 (66.2) 266/397 (67.0)
P2Y12 inhibitor 135/402 (33.6) 115/397 (29.0)
Aspirin plus P2Y12 inhibitor 113/402 (28.1) 101/397 (25.4)
Values are mean  SD, n (%), or n/N (%). There were no signiﬁcant (p < 0.05) between-group differences.
*The logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) is calculated by means of a
logistic-regression equation; online and downloadable versions of the EuroSCORE calculator are available on the
EuroSCORE Web site.
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2864In terms of the secondary outcomes at 48 h, the
rate of net adverse cardiovascular events was 8.9%
with bivalirudin and 12.6% with heparin (relative
risk: 0.71; 95% CI: 0.47 to 1.06; p ¼ 0.09). Rates of
major adverse cardiovascular events were 3.5% with
bivalirudin and 4.8% with heparin (relative risk: 0.73;
95% CI: 0.37 to 1.43; p ¼ 0.35). Rates of stroke or death
did not differ between study treatments. Myocardial
infarction was more frequent with heparin (0% vs.
1.3%; p ¼ 0.03), whereas acute kidney injury was more
frequent with bivalirudin (10.9% vs. 6.5%; p ¼ 0.03),
driven mainly by an increase in stage 1 injury.
At 30-day follow-up, rates of composite major
adverse cardiovascular events were similar between
the randomized treatments, whereas the differences
in myocardial infarction and acute kidney injury
noted at 48 h were no longer signiﬁcant. BARC $3b
bleeding occurred in 78 (9.7%) patients overall and
was associated with a mortality rate of 20.5%,whereas BARC 1 or 2 bleeding (n ¼ 214 [26.7%]) had a
mortality rate of 2.3% (Online Table 2). BARC $3
bleeding occurred in 216 (26.9%) patients and was
associated with a mortality rate of 10.6%. There were
no signiﬁcant differences between treatment groups
regarding these bleeding results.
In subgroup analyses, rates of major bleeding with
self-expanding TAVR (5.7% with bivalirudin vs. 10.6%
with heparin; relative risk: 0.54; p ¼ 0.14) or balloon-
expandable TAVR (7.6% with bivalirudin vs. 8.0%
with heparin; relative risk: 0.94; p ¼ 0.85) were
similar. Neither valve type nor sheath size ($18-F
vs. <18-F) seemed to affect the rate of major bleeding
(Online Figure 1).
Major vascular complications at 30 days, with or
without major bleeding, did not differ between the
2 groups (Online Table 3). Most differences in acute
kidney injury were mild (stage 1) (Table 3) and
occurred in the subgroup with baseline estimated
glomerular ﬁltration rate <30 ml/min (Online
Table 4); no other signiﬁcant outcome differences
were observed in this subgroup (Online Table 5).
DISCUSSION
In patients undergoing transfemoral TAVR, proce-
dural anticoagulation with bivalirudin did not
signiﬁcantly reduce the primary outcomes of major
bleeding at 48 h or net adverse cardiovascular events
at 30 days compared with heparin. Analysis of sec-
ondary outcomes also did not demonstrate any
important differences between study treatments,
indicating that bivalirudin may be used as an alter-
native to heparin during TAVR without any superi-
ority claim and taking into account the much higher
cost associated with its current use.
The primary hypothesis of BRAVO-3 was that
bivalirudin would reduce major bleeding compared
with heparin in TAVR procedures to an extent similar
to that observed in coronary intervention trials
(9,10,17,18). Although a statistically signiﬁcant dif-
ference in the primary endpoint of BARC $3b bleeding
was not observed, numerically lower major bleeding
rates were noted with bivalirudin that were also
consistent with the TIMI major bleeding deﬁnition.
These results likely reﬂect the substantial differences
that exist between the coronary and TAVR patient
populations and the respective procedures because
considerably larger arterial sheath/catheter sizes are
used in TAVR. The lack of statistically signiﬁcant dif-
ferences in overall bleeding rates between treatment
groups in the present study may also be due to sample
size limitation (despite the attempt to overcome this
factor by using an adaptive trial design).
TABLE 2 Procedural Information
Bivalirudin
(n ¼ 404)
Heparin
(n ¼ 398)
Procedural success* 393 (97.3) 388 (97.5)
Valve type
Balloon expandable 251/395 (63.5) 249/392 (63.5)
Self-expanding 140/395 (35.4) 142/392 (36.2)
Nonballoon active expansion 4/395 (1.0) 1/392 (0.3)
Duration of procedure, min 35.0 (24–50) 36.0 (24–49)
Sheath size of valve system
<18-F 128/393 (32.6) 127/390 (32.6)
18-F 216/393 (55.0) 208/390 (53.3)
>18-F 49/393 (12.5) 55/390 (14.1)
Valvuloplasty performed 325/401 (81.0) 313/395 (79.2)
Additional TAVR device used 16/395 (4.1) 12/393 (3.1)
Embolic protection device used 7/397 (1.8) 4/393 (1.0)
Closure technique used for valve
implantation access site
Not attempted 4/396 (1.0) 3/393 (0.8)
Successful deployment 359/396 (90.7) 367/393 (93.4)
Attempted but failed 33/396 (8.3) 23/393 (5.9)
Antiplatelet therapies
Prior loading with clopidogrel† 152/402 (37.8) 142/397 (35.8)
Post-procedural
Aspirin 343/401 (85.5) 348/397 (87.7)
P2Y12 inhibitor‡ 299/401 (74.6) 296/397 (74.6)
Aspirin plus P2Y12 inhibitor 264/401 (65.8) 262/397 (66.0)
Post-procedural oral anticoagulant therapy 111/400 (27.8) 119/397 (30.0)
#48 h§ 31/400 (7.8) 39/397 (9.8)
>48 h to <30 days 90/400 (22.5) 91/397 (22.9)
Values are n (%), n/N (%), or median (interquartile range). There were no signiﬁcant (p < 0.05) between-group
differences. *Valve implantation without intraprocedural major adverse cardiovascular events or conversion to
thoracotomy. †Neither prasugrel nor ticagrelor was used. ‡Clopidogrel (575 of 798 [72.1%]), prasugrel (1 of 798
[0.1%]), or ticagrelor (3 of 798 [0.4%]). §Vitamin K antagonist (50 of 797 [6.2%]), dabigatran (6 of 797 [0.8%]),
rivaroxaban (4 of 797 [0.1%]), or fondaparinux (10 of 797 [1.2%]).
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2865Major bleeding is an important concern in complex
procedures such as TAVR, in which large arterial
sheaths are used in high-risk patients. The higher
mortality in patients with BARC $3b bleeding within
30 days (20.5%) compared with that in patients with
BARC 1 or 2 (2.3%) bleeding illustrates the signiﬁcance
of bleeding complications after TAVR in relation to
mortality. In the present study, there was no signiﬁ-
cant difference in bleeding or mortality between the
groups despite numerically more failures in access
site device closure in the bivalirudin arm. Among
patients who did not have a BARC bleeding event,
mortality was very low (overall: 3.3%; bivalirudin:
2.5%; heparin: 4.2%).
The co-primary endpoint of net adverse cardio-
vascular events at 30 days did not differ between the
groups. The data observed regarding risk differences
(upper limit of 95% CI of 3.25%) would also be sig-
niﬁcant for an absolute noninferiority margin of 4%
(i.e., smaller margin than the prespeciﬁed 8%). This
combined endpoint of bleeding and ischemic events
includes the counterbalance of anticoagulation ben-
eﬁts in the prevention of ischemic events with
bleeding risks. In this ﬁrst randomized trial of TAVR
pharmacology, the dosage experience of coronary
interventions was largely utilized; in this context, our
ﬁndings suggest correct dosing for bivalirudin (i.e.,
no obvious underdose or overdose of study drug),
which was sufﬁcient to prevent ischemic events
without increasing the risk of bleeding compared
with heparin despite the unavailability of a bivalir-
udin antidote. A similar dosage was also used in 2
nonrandomized, smaller cohort studies with bivalir-
udin in valvuloplasty and TAVR (13,14).
The composite of major adverse cardiovascular
events is an important endpoint for all cardiac in-
terventions, especially high-risk procedures such as
TAVR. Although the rates of death (1.5% for bivalirudin
vs. 1.8% for heparin) and stroke (2.0% for both) at 48 h
were low overall and similar between the groups, no
myocardial infarctions occurred in the bivalirudin arm
compared with 5 in the heparin arm (1.3%, p ¼ 0.03). At
30 days, there were no signiﬁcant differences in the
rates of death, myocardial infarction, or stroke. Pa-
thology data have indicated the presence of tissue fac-
tor in the leaﬂets of stenotic aortic valves (19,20).
Exposure of tissue factor to the circulation during TAVR
may create a highly thrombogenic local substrate.
Whether more effective suppression of this process
with direct thrombin inhibition may be the basis of the
aforementioned ﬁndings in relation to myocardial
infarction rates remains to be tested in future trials.
Alternatively, the difference observed in rates of early
myocardial infarction may be due to chance (21).The overall procedural success rate in the present
study was >97%, indicating that high-quality centers
with experienced operators participated in this trial.
We observed complication rates somewhat lower
than those reported in earlier TAVR device trials
(6,22); although not directly comparable, these ﬁnd-
ings may reﬂect advances in device technology and
increased operator experience. However, the occur-
rence of these events reinforces the importance
of implementing an optimal periprocedural anti-
coagulation regimen.
Co-existing conditions are common among elderly
subjects. Our study patients had a mean age of 82
years, and approximately 30% were diabetic, 20% had
lung disease, and 5% had advanced chronic kidney
disease (stage 4 or 5). Rates of major vascular com-
plications with or without related bleeding were not
signiﬁcantly different between the study groups. The
overall rate of acute kidney injury was signiﬁcantly
higher in the bivalirudin group at 48 h (mostly
stage 1), and only a trend remained at 30 days. This
TABLE 3 Clinical Outcomes of the Intention-to-Treat Population
Bivalirudin
(n ¼ 404)
Heparin
(n ¼ 398)
Relative Risk
(95% CI) p Value
Co-primary endpoints
Major bleeding (BARC $3b) at 48 h or before discharge* 28 (6.9) 36 (9.0) 0.77 (0.48–1.23) 0.27
Net adverse cardiovascular events at 30 days 58 (14.4) 64 (16.1) 0.89 (0.64–1.24) 0.50
Secondary endpoint at 48 h or before hospital discharge*
Net adverse cardiovascular events 36 (8.9) 50 (12.6) 0.71 (0.47–1.06) 0.09
Major adverse cardiovascular events 14 (3.5) 19 (4.8) 0.73 (0.37–1.43) 0.35
Death 6 (1.5) 7 (1.8) 0.84 (0.29–2.49) 0.76
Myocardial infarction 0 5 (1.3) NA 0.03
Stroke 8 (2.0) 8 (2.0) 0.99 (0.37–2.60) 0.98
VARC (life-threatening or major) 88 (21.8) 78 (19.6) 1.11 (0.85–1.46) 0.45
TIMI (major) 16 (4.0) 26 (6.5) 0.61 (0.33–1.11) 0.10
GUSTO (severe/life-threatening) 15 (3.7) 13 (3.3) 1.14 (0.55–2.36) 0.73
ACUITY/HORIZONS (major) 105 (26.0) 97 (24.4) 1.07 (0.84–1.35) 0.60
BARC 3a 63 (15.6) 53 (13.3) 1.17 (0.84–1.64) 0.36
BARC 1 and 2 84 (20.8) 84 (21.1) 0.99 (0.75–1.29) 0.91
TIMI minor 67 (16.6) 57 (14.3) 1.16 (0.84–1.60) 0.38
Transient ischemic attack 0 0 NA NA
Acute kidney injury 44 (10.9) 26 (6.5) 1.67 (1.05–2.65) 0.03
Stage 1 33 (8.2) 22 (5.5) 1.48 (0.88–2.49) 0.14
Stage 2 6 (1.5) 2 (0.5) 2.96 (0.60–14.56) 0.29
Stage 3 5 (1.2) 2 (0.5) 2.46 (0.48–12.62) 0.45
Major vascular complications 35 (8.7) 36 (9.0) 0.96 (0.61–1.49) 0.85
New onset atrial ﬁbrillation/ﬂutter 13 (3.2) 10 (2.5) 1.28 (0.57–2.89) 0.55
Thrombocytopenia 67 (16.6) 69 (17.3) 0.96 (0.70–1.30) 0.78
Secondary endpoint at 30 days
Major bleeding (BARC $3b) 36 (8.9) 42 (10.6) 0.84 (0.55–1.29) 0.43
Major adverse cardiovascular events 31 (7.7) 32 (8.0) 0.95 (0.59–1.53) 0.85
Death 19 (4.7) 19 (4.8) 0.99 (0.53–1.83) 0.96
Myocardial infarction 2 (0.5) 7 (1.8) 0.28 (0.06–1.35) 0.11
Stroke 14 (3.5) 11 (2.8) 1.25 (0.58–2.73) 0.57
Transient ischemic attack 0 0 NA NA
Acute kidney injury 76 (18.8) 55 (13.8) 1.36 (0.99–1.87) 0.06
Stage 1 60 (14.9) 46 (11.6) 1.28 (0.90–1.84) 0.17
Stage 2 10 (2.5) 5 (1.3) 1.97 (0.68–5.71) 0.20
Stage 3 6 (1.5) 5 (1.3) 1.18 (0.36–3.84) 0.78
Major vascular complications 37 (9.2) 38 (9.5) 0.96 (0.62–1.48) 0.85
New onset atrial ﬁbrillation/ﬂutter 22 (5.4) 16 (4.0) 1.35 (0.72–2.54) 0.34
Thrombocytopenia 97 (24.0) 92 (23.1) 1.04 (0.81–1.33) 0.77
Values are n (%), unless otherwise speciﬁed. *Whichever occurred ﬁrst.
ACUITY/HORIZONS ¼ Acute Catheterization and Urgent Intervention Triage Strategy/Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial
Infarction; BARC ¼ Bleeding Academic Research Consortium; CI ¼ conﬁdence interval; GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries; NA ¼ not applicable; TIMI ¼ Thrombolysis In Myocardial Infarction; VARC ¼ Valve Academic Research Consortium.
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2866unexpected ﬁnding has not been reported before
(7–12), and no plausible biological mechanism
exists. Although acute kidney injury was more
frequent in the bivalirudin group at 30 days, this
ﬁnding did not seem to affect mortality compared
with the heparin arm, even in patients with advanced
kidney disease at baseline. Finally, patients were
stratiﬁed during randomization according to balloon-
expandable (63.5%) or self-expanding (35.8%) valves;
the main study outcomes were not affected by the
valve type.STUDY LIMITATIONS. BRAVO-3 was an open-label
trial and may be subject to treatment bias, and data
on standard of care were not available from all sites.
The procedure (including heparin dosing and admin-
istration, and the decision on whether to use prot-
amine reversal) and the use of antithrombotic
therapies post-procedurewere performed according to
standard local institution practices. Although this
approach may lead to inconsistency in the comparator
groups, it is also representative of everyday clinical
practice. Finally, the lack of data on protamine use
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Among patients with severe aortic stenosis undergo-
ing TAVR, intraprocedural anticoagulation with the
direct thrombin inhibitor bivalirudin was noninferior
but not superior to unfractionated heparin with
respect to major bleeding at 48 h or adverse events at
30 days after the procedure.
TRANSLATIONAL OUTLOOK: Further research is
needed to deﬁne the optimum antithrombotic stra-
tegies during and after TAVR.
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2868prevented us from performing subgroup analyses in
patients who did or did not undergo heparin reversal.
CONCLUSIONS
Procedural administration of bivalirudin, compared
with unfractionated heparin, did not meet superior-
ity because it did not reduce the co-primary out-
comes of BARC $3b major bleeding at 48 h or net
adverse cardiovascular events at 30 days in high-risk
or inoperable patients with severe, symptomatic
aortic stenosis undergoing TAVR. In addition, given
heparin’s lower cost, this agent should remain the
standard of care, and bivalirudin may be an alterna-
tive anticoagulant for the minority of patients
who cannot receive heparin in TAVR procedures
(e.g., because of heparin-induced thrombocytopenia
or allergy).
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APPENDIX For a complete list of the
BRAVO-3 investigators (Valve Pharmacology
Consortium), as well as a full description of the
Methods and additional Results, please see the
online version of this article.
